Background/Aims: We investigated insulin-like growth factor 2 (IGF-2) gene activity in human uterine fibroid tissue. Results of the genetic testing were correlated with clinical data. Methods: We obtained samples from patients treated for uterine fibroid and from patients undergoing hysterectomy due to other indications (control group). The examined group (with fibroid) contained 101 cases, while the control group was similar with 110 patients. Gene expression values were determined using the standard PCR technique. Clinical data were available from the computer database of the department. Results: IGF-2 gene expression was significantly higher in the fibroid group. There was no correlation between increase in gene activity and the number of tumors. History of previous uterine fibroid did not seem to predict IGF-2 gene activity in the current fibroid tumor tissue. IGF-2 gene expression did not correlate with cumulative duration of lactation following prior pregnancies. Conclusion: IGF-2 gene activity is significantly increased in leiomyoma tissue compared to normal myometrium. Familial aggregation of uterine fibroids is not significantly associated with increased IGF-2 gene activity; other genes may have a stronger etiological role. It appears that the genetic factors potentially important in the development of familiar uterine leiomyoma are not related to the IGF-2 gene.

Keywords:
Uterine fibroid, Leiomyoma, Insulin-like growth factor 2, Gene expression, Bleeding disorder, Abdominal pain
1.
Okolo S: Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:571-588.
2.
Lee DY, Koo YA, Yoon BK, Choi D: Reproductive health characteristics of urban South Korean women. Gynecol Obstet Invest 2010;70:154-159.
3.
Cramer SF, Patel A: The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-438.
4.
Shikora SA, Niloff JM, Bistrian, et al: Relationship between obesity and uterine leiomyomata. Nutrition 1991;7:251-255.
5.
Marshall LM, Spiegelman D, Barbieri RL, et al: Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-973.
6.
Gross KL, Panhuysen CI, Kleinman MS, et al: Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. Genes Chromosomes Cancer 2004;41:183-190.
7.
Luoto R, Kaprio J, Rutanen EM, et al: Heritability and risk factors of uterine fibroids - the Finnish Twin Cohort Study. Maturitas 2000;37:15-26.
8.
Alam NA, Rowan AJ, Wortham NC, et al: Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer and fumarate hydratase deficiency. Hum Mol Genet 2003;12:1241-1252.
9.
Fleischer R: Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Clin Obstet Gynaecol 2008;22:603-614.
10.
Moon YS, Park SK, Kim HT, et al: Imprinting and expression status of isoforms 1 and 2 of PEG1/MEST gene in uterine leiomyoma. Gynecol Obstet Invest 2010;70:120-125.
11.
Grings AO, Lora V, Ferreira GD, et al: Protein expression of estrogen receptors α and β and aromatase in myometrium and uterine leiomyoma. Gynecol Obstet Invest 2012;73:113-117.
12.
Pahlman S, Meyerson G, Lindgren E, et al: Insulin-like growth factor I shifts from promoting cell division to potentiating maturation during neuronal differentiation. Proc Natl Acad Sci USA 1991;88:9994-9998.
13.
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
14.
Dixon D, He H, Haseman JK: Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000;108(suppl 5):795-802.
15.
Peng L, Wen Y, Han Y, Wei A, Wei JJ, et al: Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil Steril 2009;91:2664-2675.
16.
Tsibris JC, Segars J, Coppola D, et al: Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002;78:114-121.
17.
Catherino WH, Segars JH: Microarray analysis in fibroids: which gene list is the correct list? Fertil Steril 2003;80:293-294.
18.
Hoffman PJ, Milliken DB, Gregg LC, et al: Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004;82:639-649.
19.
Skubitz KM, Skubitz AP: Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003;141:297-308.
20.
Rainho CA, Pontes A, Rogatto SR: Expression and imprinting of insulin-like growth factor II (IGF2) and H19 genes in uterine leiomyomas. Gynecol Oncol 1999;74:375-380.
21.
De Leo V, la Marca A, Morgante G, Severi FM, Petraglia F: Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Fertil Steril 2001;75:632-633.
22.
Schulz, TW, Griffin S: Estimating risk assessment exposure point concentrations when the data are not normal or lognormal. Risk Anal 1999;19:577-584.
23.
Nohara A, Ohmichi M, Koike K, et al: Prolactin stimulates mitogen-activated protein kinase in human leiomyoma cells. Biochem Biophys Res Commun 1997;238:473-477.
24.
Gupta S: Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:615-622.
25.
Boehm KD, Daimon M, Gorodeski IG, et al: Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 1990;27:93-101.
26.
Ahn WS, Kim KW, Bae SM, Yoon JH, Lee JM, Namkoong SE, Kim JH, Kim CK, Lee YJ, Kim YW: Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol 2003;84:267-279.
27.
Marshall LM, Spiegelman D, Goldman MB, et al: A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-439.
28.
Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, Dey SK, Dotto GP, Weinberg RA: IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002;3:877-887.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.